Independent review identified, no safety concerns in trial's final safety run-in
Cohort supported by prior clinical data showing a pelareorep-based combination driving a 90% clinical benefit rate in KRAS-mutated colorectal cancer patients
Multi-indication trial being conducted in collaboration with Roche and AIO also includes pancreatic and advanced anal cancer cohorts
https://finance.yahoo.com/news/oncolytics-biotech-provides-positive-safety-110000865.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.